Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10
04 Janeiro 2022 - 10:00AM
Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, announces that Michael
Nall, President and CEO, will present a company overview at the
H.C. Wainwright BioConnect Virtual Conference being held January
10-13, 2022. A webcast of the Biocept presentation can be accessed
on the Investor Relations section of the company website beginning
on January 10, 2022 at 7:00 a.m. Eastern time.
“Our priority in 2022 is to continue generating clinical data in
order to further support adoption of CNSide™, our proprietary
cerebrospinal fluid assay for diagnosing and managing tumors that
have metastasized to the central nervous system,” said Mr. Nall.
“CNSide addresses a high unmet clinical need as metastatic brain
cancer is extremely difficult to accurately diagnose using
traditional tools and approaches. Physicians are using CNSide,
together with newer therapies that target specific cancer
mutations, to help patients who may have limited treatment
options.
“We proudly continue assisting in the fight against the pandemic
with RT-PCR COVID-19 testing services, which in turn, is helping to
fund our long-term oncology strategy,” he added. “We are pleased to
begin the New Year by sharing our company presentation with the
investment community.”
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information to aid in the diagnosis, treatment and monitoring of
patients with cancer. In addition to its broad portfolio of
blood-based liquid biopsy tests, the company has developed the
CNSide™ cerebrospinal fluid assay, designed to diagnose cancer that
has metastasized to the central nervous system. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide RT-PCR-based COVID-19 testing and services to support
public health efforts during this unprecedented pandemic. For more
information, visit www.biocept.com. Follow Biocept on Facebook,
LinkedIn and Twitter.
Forward-Looking Statements Disclaimer
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although Biocept believes that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, Biocept can
give no assurance that such expectations and assumptions will prove
to have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "could,"
"expect," or "believe" or the negative of these words or other
variations on these words or comparable terminology. To the extent
that statements in this release are not strictly historical,
including without limitation statements regarding the capabilities
and potential benefits of Biocept’s CNSide assay and the ability of
Biocept’s assays to provide physicians with clinically actionable
information, such statements are forward-looking, and are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The reader is cautioned not to put
undue reliance on these forward-looking statements, as these
statements are subject to numerous risks and uncertainties,
including the risk that Biocept’s products and services may not
perform as expected. These and other risks are described in greater
detail under the "Risk Factors" heading of Biocept’s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2021, filed
with the Securities and Exchange Commission (SEC) on November 15,
2021. The effects of such risks and uncertainties could cause
Biocept’s actual results to differ materially from the
forward-looking statements contained in this release. Biocept does
not plan to update any such forward-looking statements and
expressly disclaims any duty to update the information contained in
this press release except as required by law. Readers are advised
to review Biocept’s filings with the SEC, which can be accessed
over the Internet at the SEC's website located at www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220104005341/en/
Investor Contact: Jody Cain, LHA Investor Relations
Jcain@lhai.com, 310-691-7100
Media Contact: Andrea Sampson, Sampson PR Group
asampson@sampsonprgroup.com, 562-304-0301
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024